Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

CARDIO CAR-engineered Cell therapy for Cardiovascular diseases

Coordinator
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, Germany
Runs
1 October 2026 to 30 September 2030
Status
Running
EU funding
€6.9m
Total cost
€7.0m
Partners
7 organisations in 3 countries
Type
Research and Innovation Action
Grant agreement
101289864

What the project is doing

In the project's own words, from its summary on CORDIS.

CARDIO will develop a next-generation immunotherapy based on gene-engineered regulatory T cells (Tregs) to restore immune homeostasis during acute and chronic inflammation in cardiovascular disease. Myocardial infarction (MI), often caused by atherosclerosis (AS), is a leading cause of death in Europe—affecting one in seven women and one in six men. MI results from thrombotic occlusion following plaque rupture or erosion, leading to myocardial ischemia, cell death, and a self-perpetuating inflammatory response.

This unresolved inflammation impairs tissue repair, drives adverse remodeling, and contributes to both acute and chronic heart failure (HF), with devastating impacts on patient quality of life and survival. Given the heart’s negligible regenerative capacity, CARDIO will utilize Tregs to (i) suppress chronic inflammation within atherosclerotic plaques, preventing their rupture, and (ii) disrupt the acute inflammatory cycle post-MI to support myocardial healing.

CARDIO Tregs will be derived from healthy donors as an allogeneic, virus-free gene-engineered “off-the-shelf” product. To enhance specificity and function, they will be equipped with chimeric antigen receptors (CARs) targeting myocardial (MYOCAR) and atherosclerotic (ASCAR) antigens. Upon antigen recognition, these CAR Tregs will secrete tolerogenic cytokines and suppress inflammatory macrophages and T cells—key drivers of fibrosis and plaque progression.

Using in vivo CRISPR screening and protein engineering, CARDIO will tailor Tregs to inflammatory niches, ensuring stability and effective immune modulation. The ultimate goal is to deliver the first cellular immunotherapy for reducing atheroprogression and improving post-MI recovery—transforming outcomes for patients and reducing cardiovascular mortality.

Who is involved

OrganisationCityCountryRole
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-UniversitatWurzburgGermanyCoordinator
Cemm - Forschungszentrum Fuer Molekulare Medizin GmbHWienAustriaParticipant
Universitaet Fuer Bodenkultur WienWienAustriaParticipant
Bayerische Forschungsallianz Bavarian Research Alliance GmbHMunchenGermanyParticipant
DKMS Group gGmbHTubingenGermanyParticipant
T-Curx GmbHWurzburgGermanyParticipant
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (f.s.p.)MadridSpainParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI